ARID1A-deficient cancers are dependent on the non-catalytic role of the zeste 2 polycomb repressive complex 2 subunit (EZH2), promising therapeutic utility for ARID1A-deficient tumors [210]. The gene discussed is ARID1A; the disease is cancer.